IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION May 2026 Update Filed in 2016 and centralized in the Eastern District of Pennsylvania, the Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) remains one of the largest and most complex antitrust cases in the U.S. The litigation alleges that multiple generic drug manufacturers conspired to fix prices, allocate markets, and limit competition across hundreds of generic drugs. Current Status (2026) This

Over $115.2 Million via Pharmaceutical Benefit Plan Settlements, separate from the Generic Pharmaceuticals Pricing Antitrust Litigation. Overview There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or

Updated: August 2022 IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION Case Overview Entities in every link in the chain of opioid drug...